• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Press release

Scandinavian ChemoTech's Animal Care Surpasses 3,000 Treatments Performed Worldwide

Scandinavian ChemoTech

Scandinavian ChemoTech's Animal Care, a pioneer in making oncology care more compassionate and human for animals, proudly announces another achievement: over 3,000 treatments have now been performed in veterinary medicine worldwide, using its advanced vetIQure® TSE Tumor Specific Electroporation™ technology. This achievement represents thousands of families who have gained more time, comfort, and hope with their beloved companions.

Since launch, vetIQure TSE technology has been embraced by veterinarians across the globe, with 75% of treatments performed in the United States and 25% in international markets. Its rapid adoption reflects not only the technology's clinical value, but also the growing commitment among veterinarians to offer advanced cancer care to pet owners everywhere.

 

A particularly noteworthy success story comes from a clinic in South Florida, which has performed over 150 treatments within its first six months of vetIQure TSE operation, making it the fastest clinic to reach this milestone since the technology's introduction. This achievement underscores both the clinic's dedication to innovation and the accelerating momentum of vetIQure TSE adoption among leading veterinary oncology centers.

 

"It's a great feeling to be part of something so meaningful - to be one of the inventors and co-founders of a company whose work truly changes lives. Every treatment represents a patient, whether human or animal, whose quality of life has been improved, cured, or extended, and a family who has been given more moments of love and connection," says Mohan Frick, CEO at Scandinavian ChemoTech. "I'm incredibly proud to continue leading our dedicated teams at ChemoTech and VQ Animal Care, who are transforming years of research and passion into real impact for both animals and humans"

 

Looking ahead, Scandinavian ChemoTech's Animal Care is dedicated to expanding access to this life-changing technology. Upcoming milestones include reaching 100 devices deployed globally and treating more than 5,000 animals, ensuring that more veterinarians-and more pets-can benefit from advanced oncology care.